Hira Shaikh
@hiragss
Followers
366
Following
454
Media
42
Statuses
214
Myeloma and transplant staff physician at @uihealthcare. Alumnus @uofcincy. Pakistani. Advocate #Socialjustice #Kindness Interests #Traveler #Photographer
United States
Joined August 2011
RT @myelomadoctor: 📢 Excited to share our multicenter study just published in Clinical Lymphoma, Myeloma & Leukemia:. “Real-world outcomes….
clinical-lymphoma-myeloma-leukemia.com
MicroabstractAs the ideal sequencing of BCMA directed therapies has not been established, this study aimed to assess the real-world outcomes of patients treated with BCMA-directed therapies following...
0
8
0
RT @mumairmushtaq: Talquetamab in Heavily Pretreated Multiple Myeloma Patients, Including BCMA-Refractory .@KUcance….
0
6
0
RT @Abdallah81MD: 8/🧱 Limitations:.- Retrospective nature.- Relatively small cohort size.- Potential variability in follow-up periods and s….
0
2
0
RT @Abdallah81MD: 7/Prognostic Factors:.•Multivariate analysis identified prior bispecific antibody exposure (HR 3.87, p=0.01) & extramedul….
0
2
0
This is probably the lead takeaway from the study. Unfortunately not all patients can afford a 6 month break between therapies. However, when possible this needs to be prioritised. T cells need a break. And sequencing therapies in #mmsm is becoming a bigger problem.
6/The timing of prior BDT relative to talquetamab initiation also appeared to influence outcomes. BDT immediately preceding talquetamab or BDT within 6 months of starting talquetamab was associated with lower ORR and shorter PFS & OS on univariate analysis. - ORR was lower when
0
4
4
RT @Abdallah81MD: 5/🤔Impact of Prior Bispecific Antibody Exposure and BCMA-Directed Therapy (BDT):.♾️ Prior exposure to bispecific T-cell e….
0
2
0
Hence, limited duration treatment needs to be evaluated for these drugs in #mmsm @AlGarfall is leading LimiTEC study which studies limited duration bispecific. Also open at @uiowa @strouse_chris and Columbia @rajshekharucms.
4/ ⛔️Discontinuation and dose reduction:. - 43% required treatment interruption, mainly due to toxicities . (the challenge of continuous drug use due to unique toxicities and cytopenias). #mmsm #myeloma #MedEd #medtwitter @OncoAlert @USMIRCNEWS #USMIRC #سرطان_الدم #المايلوما.
0
4
7
RT @Abdallah81MD: 3/ 🛑Safety: The overall safety profile was similar to MonumenTAL-1, with cytopenias being the most frequent and severe a….
0
2
0
RT @Abdallah81MD: 2/ ⚛️ Efficacy in comparison to MonumenTAL-1:.The real-world study ORR of 71%, with 51% achieving ≥ VGPR & 25% achieving….
0
3
0
I could not have come up with a better summary. Excited to share our article on RWE of talquetamab in #mmsm. Also the first publication of BloodICT @BloodAdvances @Abdallah81MD @NausheenAhmedMD @mumairmushtaq @AlmaHabibMD @j_snyder0132 @AtrashShebli @strouse_chris @myelomadoctor.
🧵Talquetamab in Heavily Pretreated Multiple Myeloma Patients, Including BCMA-Refractory:. 1/ ⚖️This real-world retrospective study of heavily pretreated multiple myeloma patients across seven US academic centers found that the safety and efficacy of talquetamab were generally
0
5
12
Honoured to author the first publication of BloodICT @BloodAdvances.
🚨🎉🎊Congratulations to Blood Immunology & Cellular Therapy first published paper, Talquetamab in Heavily Pretreated Multiple Myeloma Patients, Including BCMA-Refractory.
0
1
9
Excited to have the opportunity to talk about #mmsm and connect with fellow Iowan oncologists I have been on phone with plenty of times. @binaytara.
Dr. Tara Graff from @missioncancer_ and @hiragss of @uihealthcare combine their knowledge to share about lymphoid malignancies at #BTFHemBreast25 in Des Moines. Session Chair: @strouse_chris of @uihealthcare. 🌟 Visit for more upcoming CME conferences!
0
2
9
So proud and excited for our trainee @mehndz at @UIowaCancer @uihealthcare being selected as fellow of the month @OncData and sharing her journey.
March's Fellow of the Month is Dr. Mehndi Dandwani (@mehndz), a 1st-year #HemeOnc #Fellow at @uihealthcare! Watch as she discusses her journey to becoming a physician, her #research interests, and what she enjoys most about being a fellow. Watch here!
2
1
9
Great work @Rachel_DiLeo5 and @hhashmi87.
📢 New Publication Alert!. Excited to share our latest study in Blood Cancer Journal (IF 12.9) on real-world efficacy & safety of belantamab mafodotin in relapsed refractory multiple myeloma. 🔹 ORR: 40% in high-risk, heavily pretreated patients.🔹 EMD linked to poorer outcomes.
0
0
1
RT @myelomadoctor: 📢 New Publication Alert!. Excited to share our latest study in Blood Cancer Journal (IF 12.9) on real-world efficacy & s….
0
7
0
Hoping to see follow-up and label changes with this poster by @RahulBanerjeeMD on a ❓I and my patients ask repeatedly - Is 8 week driving restriction post-BCMA CART necessary? #Tandem25.@RahulBanerjeeMD Kudos for finding ways to answer ❓affecting #QOL in #mmsm
1
1
15
Our @UIowaCancer #mmsm led BCMA CART manufacturing failure project presented at #Tandem25 . Time from Cytoxan affected successful manufacturing. Limited number of pts with TCE bsAb exposure. Brainchild of @strouse_chris Collab with @thisisJamesD @USMIRCNEWS
0
5
8
RT @myelomadoctor: 📌 Visit our 4 posters in Exhibit Hall 3 (HCC), covering key insights into BCMA-directed therapies, ASCT outcomes, CAR-T….
0
8
0
Proud of our @USMIRCNEWS team for putting out so many posters at #Tandem2025 Highlighting this very relevant ❓ of options in BCMA exposed RRMM #mmsm by @j_snyder0132 @Abdallah81MD @myelomadoctor @NausheenAhmedMD @mumairmushtaq @hhashmi87 @thisisJamesD
0
3
11